Browse All

Current Filters

CLEAR FILTER x

TITLE

Efficacy and Safety of ES-481, a Novel TARP Inhibitor, in Drug-resistant Epilepsy: A Double-blind Randomized Placebo Controlled Phase IIa Trial

Author:O'Brien, Terence   Foster, Emma   Millist, Lyn   Germaine, Jack   Chamorro, Stephanie   Roberts, Caitlyn   Nicolo, John Paul   Hosking, Sean   Perucca, Piero   Mullen, Saul   Robinson, Heather   Wharrie, Bec   Walsh, Brittany   Reutens, David   Irwin, Kimberley   Chen, Michael   Niecestro, Robert   

Session Name:S19: Epilepsy Clinical Trials and Long-term Studies  

Topic:Epilepsy/Clinical Neurophysiology (EEG)  

Program Number:S19.003  

Author Institution:Monash University, Melbourne, Vic, Australia  Alfred Health, Melbourne, Vic, Australia  The Royal Melbourne Hospital, Parkville, Vic, Australia  Austin Health, Heidelberg, Australia  Austin Health, Heidelburg, Vic , Australia  The Royal Brisbane and Womens Hospital, Herston, QLD, Australia  ES Therapeutics, New York, NY  

Pregnancy Outcomes Following Exposure to Lacosamide: Prospective Data from Spontaneous and Solicited Reports

Author:Perucca, Piero   Bourikas, Dimitrios   Voinescu, P Emanuela   Vadlamudi, Lata   Chellun, Daya   Kumke, Thomas   Werhahn, Konrad J.   Schmitz, Bettina   

Session Name:P4: Epilepsy/Clinical Neurophysiology (EEG): Epilepsy Co-morbidities and Special Populations  

Topic:Epilepsy/Clinical Neurophysiology (EEG)  

Program Number:P4.011  

Author Institution:The University of Melbourne and Bladin-Berkovic Comprehensive Epilepsy Program, Austin Health, Melbourne, Australia  UCB Pharma, Alimos, Greece  Brigham and Women'S Hospital, Harvard Medical School, Boston, MA  Royal Brisbane and Women’s Hospital, Brisbane, Australia  UCB Pharma, Braine-l'Alleud, Belgium  UCB Pharma, Monheim am Rhein, Germany  Vivantes Humboldt-Klinikum, Berlin, Germany